Harrow Health, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Harrow Health, Inc.
The company known for compounding versions of Martin Shkreli’s Daraprim and Allergan’s Restasis is hit with a warning letter for promotions in professional periodicals about its compounded eye drop.
Approval of Alaway Preservative Free (ketotifen fumarate, 0.035) comes 15 months after FDA submitted a complete response letter to Bausch and the active ingredient developer, Eton Pharmaceuticals.
October has not been kind to biotech stocks, but that hasn't stopped drug developers from launching IPOs in the US. Also, Takeda reconfigures debt ahead of Shire deal and other offerings.
The average return for the 54 drug developers that went public in the US during first three quarters of 2018 was 13.6% as of Oct. 1 versus 16.9% as of Aug. 31 for the 47 biopharma firms that launched IPOs during the first eight months of this year. September had seven new offerings after just two in August.
- Specialty Pharmaceuticals
- Site Specific
- Topical Delivery
- Other Names / Subsidiaries
- Imprimis Pharmaceuticals, Inc.
- Mayfield Pharmaceuticals
- Melt Pharmaceuticals, Inc.
- Pharmacy Creations LLC (PC)
- Radley Pharmaceuticals
- Surface Pharmaceuticals, Inc.
- Transdel Pharmaceuticals, Inc.